Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanborn

Showing results (981-990 of 996) with videos related to

Pageof 100
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2021
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I StudyKeunchil Park, Eric B Haura, Natasha B Leighl, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 19, 2011
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinomaNicholas J Wang, Zachary Sanborn, Kelly L Arnett, et al.
Nature Electronics|July 3, 2026
A wireless subdural-contained brain-computer interface with 65,536 electrodes and 1,024 channelsTaesung Jung, Nanyu Zeng, Jason D Fabbri, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 studyMariam Alexander, Ying Cheng, Se-Hoon Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort ABenjamin Besse, Koichi Goto, Yongsheng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 StudyNatasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|August 28, 2020
Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19 Multinational RegistryJames E Siegler, Pere Cardona, Juan F Arenillas, et al.
Cell|October 15, 2013
The somatic genomic landscape of glioblastomaCameron W Brennan, Roel G W Verhaak, Aaron McKenna, et al.
Science (New York, N.Y.)|November 9, 2013
Chelyabinsk airburst, damage assessment, meteorite recovery, and characterizationOlga P Popova, Peter Jenniskens, Vacheslav Emel'yanenko, et al.
Meteoritics & Planetary Science|July 23, 2021
The impact and recovery of asteroid 2018 LAPeter Jenniskens, Mohutsiwa Gabadirwe, Qing-Zhu Yin, et al.
Pageof 100

Showing results (981-990 of 996) with videos related to

Sort By:
Pageof 100
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2021
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I StudyKeunchil Park, Eric B Haura, Natasha B Leighl, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 19, 2011
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinomaNicholas J Wang, Zachary Sanborn, Kelly L Arnett, et al.
Nature Electronics|July 3, 2026
A wireless subdural-contained brain-computer interface with 65,536 electrodes and 1,024 channelsTaesung Jung, Nanyu Zeng, Jason D Fabbri, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 studyMariam Alexander, Ying Cheng, Se-Hoon Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort ABenjamin Besse, Koichi Goto, Yongsheng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 StudyNatasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|August 28, 2020
Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19 Multinational RegistryJames E Siegler, Pere Cardona, Juan F Arenillas, et al.
Cell|October 15, 2013
The somatic genomic landscape of glioblastomaCameron W Brennan, Roel G W Verhaak, Aaron McKenna, et al.
Science (New York, N.Y.)|November 9, 2013
Chelyabinsk airburst, damage assessment, meteorite recovery, and characterizationOlga P Popova, Peter Jenniskens, Vacheslav Emel'yanenko, et al.
Meteoritics & Planetary Science|July 23, 2021
The impact and recovery of asteroid 2018 LAPeter Jenniskens, Mohutsiwa Gabadirwe, Qing-Zhu Yin, et al.
Pageof 100